Filing Flows › BioAge Labs (BIOA) › Stock forecast & fair value
BioAge Labs (BIOA) stock forecast and price target
BioAge Labs (BIOA) trades at $5.34. 9 analysts' median price target is $25.00 (+368%), from $8.00 to $73.00.
BioAge Labs' latest quarter
BioAge Labs, Q3 2026: revenue $298K (-86% year over year), net loss $33.5M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BIOA stock?
The median of 9 analysts' 12-month targets is $25.00, +368% from $5.34; the range is $8.00 to $73.00. The average rating is buy.
Does BioAge Labs usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is BIOA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.